<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31870202</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1563-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The International journal of neuroscience</Title><ISOAbbreviation>Int J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review.</ArticleTitle><Pagination><StartPage>727</StartPage><EndPage>735</EndPage><MedlinePgn>727-735</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00207454.2019.1702549</ELocationID><Abstract><AbstractText><b>Aim of the study:</b> We conducted a systematic review on existing literature in humans and animals, linking the gut microbiome with amyotrophic lateral sclerosis (ALS). Additionally, we sought to explore the role of the bacterially produced metabolite butyrate as well as of proton pump inhibitors (PPIs) in these associations.<b>Materials and methods:</b> Following PRISMA guidelines for systematic literature reviews, four databases (Medline, Scopus, Embase and Web of Science) were searched and screened by two independent reviewers against defined inclusion criteria. Six studies in humans and six animal studies were identified, summarized and reviewed.<b>Results:</b> Overall, the evidence accrued to date is supportive of changes in the gut microbiome being associated with ALS risk, and potentially progression, though observational studies are small (describing a total of 145 patients with ALS across all published studies), and not entirely conclusive.<b>Conclusions:</b> With emerging studies beginning to apply metagenome sequencing, more clarity regarding the importance and promise of the gut microbiome in ALS can be expected. Future studies may also help establish the therapeutic potential of butyrate, and the role of PPIs in these associations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erber</LastName><ForeName>Astrid C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Headington, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8997-608X</Identifier><AffiliationInfo><Affiliation>Division of Microbial Ecology, Department of Microbiology and Ecosystem Function, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schernhammer</LastName><ForeName>Eva S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Channing Division of Network Medicine, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neurosci</MedlineTA><NlmUniqueID>0270707</NlmUniqueID><ISSNLinking>0020-7454</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002087">Butyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Microbiome</Keyword><Keyword MajorTopicYN="N">butyrate</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">proton pump inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31870202</ArticleId><ArticleId IdType="doi">10.1080/00207454.2019.1702549</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>